Home
My Account
About Us
Forum
Contact us
الواجهة العربية
epharmaweb.com
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz
Newsletter

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



Droleptan

Main

You must sign in to use this servcie


Feedback - Please use the form below to send your query or comment

You must sign in to use this servcie

Username:
Password:

Info

Indications:

Post-operative nausea and vomiting.

Contraindications:

Coma; CNS depression; phaeochromocytoma; bone marrow suppression. Patients at risk of arrhythmias, CV disorders, electrolyte imbalance, preexisting QT prolongation.

Adverse reactions:

Dry mouth, constipation, micturition difficulty, blurred vision, mydriasis, delirium, agitation, catatonic-like states, insomnia, nightmares, depression, miosis, convulsions, nasal congestion. CV effects; hypersensitivity reactions, haematological disorders, extrapyramidal dysfunction. Amenorrhoea, galactorrhoea, gynaecomastia, weight gain and hyperglycaemia, and altered glucose tolerance. Pain and irritation at the Inj site. Post-op drowsiness.

Interactions:

Avoid concurrent use with drugs that may prolong QT interval e.g. certain antihistamines, antimalarials, calcium-channel blockers and antidepressants. May potentiate the action of other CNS depressants e.g. barbiturates, alcohol. Caution when using with drugs that may induce hypokalaemia or hypomagnesemia. Lab Interference Minor abnormalities in liver function tests.

Warnings:

Hepatic or renal impairment; history of jaundice; CV disease; DM; hyperthyroidism; Parkinson’s disease; epilepsy, depression, myasthenia gravis; prostatic hypertrophy; severe respiratory disease; blood dyscrasias. May precipitate coma, affect driving. Pregnancy; lactation; elderly. pregnancy: Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Form:

SOLUTION FOR INJECTION

Dosage and Administration

You must sign in to use this servcie

Technical Description

You must sign in to use this servcie






Forgot your password


sign up

Consultants Corner

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Dr. Talal Sabouni

Dr. Talal Sabouni UROLOGY AND KIDNEY TRANSPLANT

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist
Poll

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details